High Estrogen in Men: What Raises Estradiol, and What Treating It Achieves

Not on its own. Estradiol - the main estrogen, usually printed as E2 on a lab report - is measured in men to help explain something that has already been noticed: breast tissue that has grown, testosterone that is low, a testis that feels different. The number is a clue to a cause, and it is the cause that gets treated.

The European Academy of Andrology set this out in its 2019 gynaecomastia guideline. Its recommendation R14 is that selective estrogen receptor modulators, aromatase inhibitors and non-aromatizable androgens are not recommended for breast enlargement in men in general. Recommendation R13 is that testosterone should be offered only to men with proven testosterone deficiency. Recommendation R12 is watchful waiting once an underlying cause has been treated or a drug stopped.

This matters because "lower your estrogen" is sold hard online, usually attached to a supplement or an aromatase inhibitor. The sections below set out what actually raises estradiol, what a proper assessment involves, and what happened when those drugs were tested against placebo.

If the underlying question is low testosterone rather than high estrogen, the pituitary hormones are the more informative pair - covered in FSH and LH in male infertility.

Men make estradiol mostly by converting testosterone, using an enzyme called aromatase that sits in fat, liver, bone and the testis. So estradiol rises when there is more raw material, more aromatase, or less clearance. Five routes account for most of it.

• Body fat. Fat tissue carries aromatase, and losing weight lowers estradiol while raising testosterone and the pituitary hormones. In a meta-analysis of 24 studies, total testosterone rose by 2.87 nmol/L on a low-calorie diet and 8.73 nmol/L after bariatric surgery, with estradiol falling alongside.
• Testosterone from outside the body - prescribed gel or injection, or anabolic steroids from a gym. Some of it is aromatised to estradiol, and it shuts the pituitary down. Across 1,766 steroid users, LH fell by 3.37 IU/L, FSH by 1.73 IU/L and the body's own testosterone by 10.75 nmol/L during use.
• Liver disease. In men with cirrhosis measured by mass spectrometry, median estradiol was 166.7 pmol/L against 84.6 pmol/L in age-matched controls, and estrone 869.1 against 133.8 pmol/L.
• A tumour that makes hCG, or a Leydig or Sertoli cell tumour in the testis. These are uncommon, and they are the reason the guideline asks for a testicular ultrasound and hCG and AFP blood tests rather than leaving it to a hand examination.
• Medicines and other illness. Spironolactone is the classic example; an overactive thyroid and kidney failure also feature, and both are on the guideline's list of tests.

Two of those five are self-inflicted and reversible, which is the useful news in this list. More on each in anabolic steroids and sperm damage, testosterone replacement therapy and male fertility and weight.

Less than most people assume, and this is worth knowing before acting on a single figure. The Endocrine Society's position statement on estradiol measurement concluded that while current assays are adequate for managing infertility, imprecision and differences between methods remain a problem, and the very low concentrations that matter outside reproduction are too low to be measured accurately or precisely by routine methods.

Male estradiol sits in exactly that awkward low range. The practical consequences are that a result from one laboratory cannot be read against a reference range from another, that a borderline figure is worth repeating before anything is prescribed, and that an online reference range found later is not a check on your own report.

The testosterone-to-estradiol ratio, quoted constantly in bodybuilding forums and in some clinic marketing, has no validated cut-off in men. No guideline retrieved for this article sets a threshold above which treatment is indicated - not for the ratio, and not for estradiol itself.

There is also a physical distinction that no blood test makes. Gynaecomastia is glandular breast tissue; lipomastia is fat. They look similar and feel different, and the guideline asks specifically that examination confirm palpable glandular tissue before anything is called gynaecomastia. A man carrying extra weight may have the appearance without the condition.

The purpose of the appointment is to find a cause or rule one out, not to lower a number. The European Academy of Andrology guideline is specific about what that means in practice.

1. History: when the change started, how long it has lasted, sexual development and function, and every substance taken - prescribed, over the counter, or from a gym.
2. Breast examination, to confirm whether there is glandular tissue at all and to check for anything suspicious of a breast lump.
3. Examination of the genitalia, for a testicular lump or for testes that have shrunk.
4. Testicular ultrasound. The guideline recommends it because finding a testicular tumour by feel alone has low sensitivity. This is the step most worth insisting on.
5. Blood tests: testosterone, estradiol, SHBG, LH, FSH, TSH, prolactin, hCG, AFP, and liver and kidney function.
6. Breast imaging if the examination is unclear, and a core needle biopsy straight away if a lesion looks suspicious.

Worth asking directly: is this glandular tissue or fat, has the testicular ultrasound been done, and which of my medicines could be causing it. Those three questions cover most of what gets missed.

The cost is not trivial in India and it is worth planning for. Across five tertiary centres, couples seeking infertility care reported median annual out-of-pocket spending of Rs 11,317, rising to Rs 13,211 where the problem was male-factor. In that cohort, 59.4% met the study's definition of catastrophic health expenditure - infertility spending above 40% of annual non-food household spending.

The honest answer from the trials is that these drugs reliably move the hormone numbers and have not been shown to change how men feel or look. That gap is the single most important thing on this page.

The clearest test was a randomised, double-blind, placebo-controlled trial in 80 boys aged 11-18 whose gynaecomastia had not settled over three months. Over six months on anastrozole 1 mg daily or placebo, the share achieving at least a halving of measured breast volume was 38.5% vs 31.4% (n = 80; odds ratio 1.51, 95% CI 0.50 to 4.84, P = 0.47). The median testosterone-to-estradiol ratio, by contrast, rose 166% vs 39% (n = 80). The hormones shifted. The breasts did not.

The adult evidence points the same way. Twenty-three severely obese men with hypogonadotropic hypogonadism were randomised to anastrozole plus a weight-loss programme or placebo plus the same programme for six months. The drug arm ended with higher testosterone and lower estradiol, and no difference from placebo in symptoms of hypogonadism or in muscle strength. Twenty-three men is a pilot trial, not a settled answer, but it is the controlled evidence that exists.

For fertility specifically, the evidence is thinner still. A 2026 systematic review of hormonal treatments in normogonadotropic men with abnormal semen parameters searched the literature to February 2025 and found no eligible studies of aromatase inhibitors or clomiphene at all. A 2022 review of 10 studies in 666 men did report higher sperm counts after letrozole or anastrozole, but those comparisons were against the men's own baselines rather than a control group; against active comparators there was no significant effect on sperm concentration, motility or morphology, and motility was slightly worse on the inhibitors.

On safety, short-term data are reassuring rather than alarming. In 37 elderly men with mild hypogonadism given anastrozole or placebo for 12 weeks, estradiol fell from around 26 to 17 pg/mL and markers of bone turnover and total-body bone density did not change. Twelve weeks is not a year, and no long-term bone or cardiovascular data in men were retrieved for this article.

Anti-estrogens do have a defined place, which is narrower than the marketing implies - see use of clomid in men.

Four things have evidence behind them, and all four work by removing a cause rather than by blocking the enzyme.

• Losing weight. Across 24 studies, weight loss raised testosterone and lowered estradiol, with the amount of weight lost the best single predictor of how much testosterone rose.
• Stopping anabolic steroids or non-essential exogenous testosterone. Recovery is slow: pituitary hormones came back towards baseline over 13-24 weeks, and testosterone was still below baseline at 16 weeks.
• Treating the underlying illness - liver disease, thyroid overactivity, a testicular tumour.
• Stopping or swapping a drug that causes it, where that is clinically possible, with watchful waiting afterwards rather than a second drug.

What has no supporting evidence in men is a longer list, and most of it is repeated confidently online. Avoiding soy is the clearest example: a meta-analysis of 41 studies, with estradiol measured in 1,000 men and total testosterone in 1,753, found neither soy protein nor isoflavone intake affected total testosterone, free testosterone, estradiol or estrone, at any dose and over any duration. Cutting soy out of an Indian diet achieves nothing here.

• Flaxseed, sesame and other lignan sources - no retrieved trial tests them on estradiol in men, and the advice circulating online contradicts itself in both directions.
• Ashwagandha, shatavari and turmeric - no retrieved trial measures their effect on estradiol in men.
• Zinc or magnesium as aromatase blockers or estrogen "detoxifiers" - the mechanism is asserted, not demonstrated.
• Cruciferous vegetables, organic produce and avoiding plastic - reasonable on other grounds, untested on male estradiol.

Eating well and sleeping enough are worth doing for reasons that have nothing to do with this page. Neither is a treatment for a hormone result - the wider evidence on male fertility supplements is set out in supplements that may boost male fertility.

Often. If the worry is fertility, the test that answers it is a semen analysis, not a hormone panel - and a hormone panel ordered instead of one delays the answer. If the worry is appearance, the question is whether there is glandular tissue, which is settled by examination. If the worry is low energy or low libido, testosterone and the pituitary hormones carry more information than estradiol does.

Sometimes the answer is testing, waiting, or stopping something rather than starting a drug. The guideline's own sequence is assess, treat the cause, then wait - and it reserves surgery for breast tissue that has persisted and has not settled after the cause was dealt with.

Being told to wait is a poor substitute for being told what to do, and it is reasonable to find that unsatisfying. It is still the sequence with evidence behind it. If a semen analysis is the next step, how to read the report line by line covers what the numbers mean.

Several things on this page are unresolved, and a page that hides that is less useful than one that says so.

• There is no validated estradiol level in men above which treatment is indicated, and no validated testosterone-to-estradiol ratio cut-off. No guideline retrieved for this article states one.
• Whether lowering estradiol improves how men feel is not settled. The one placebo-controlled adult trial that measured symptoms and strength found no difference, in 23 men - too few to close the question either way.
• There is no placebo-controlled evidence that aromatase inhibitors improve fertility outcomes in men. The 2026 systematic review found no eligible trials to include.
• Long-term safety of aromatase inhibitors in men is unknown. The bone data run to 12 weeks in 37 men; no longer bone or cardiovascular follow-up in men was retrieved.
• Whether raised estradiol in obesity independently affects fertility, separately from low testosterone and the other effects of obesity, was not established by any source retrieved here.
• No diet has been tested against estradiol in men. The cruciferous-vegetable, turmeric and flaxseed advice repeated across the internet rests on mechanism and on studies in women, not on male trials.
• No Indian national figure for raised estradiol or gynaecomastia prevalence in men was found. The 32-65% prevalence range above is from the European guideline.